Literature DB >> 16961629

Severe strongyloidiasis in corticosteroid-treated patients.

L Fardet, T Généreau, J Cabane, A Kettaneh.   

Abstract

Severe strongyloidiasis, caused by Strongyloides stercoralis, is a preventable life-threatening disease that can occur in any corticosteroid-treated patient who has travelled to a country with infested soil, even if the contact occurred up to 30 years previously. This diagnosis should be considered in corticosteroid-treated patients who experience either unusual gastrointestinal or pulmonary symptoms, or who suffer from unexplained sepsis caused by Gram-negative bacilli. Peripheral eosinophilia is not observed systematically and, even if present, is moderate in most cases. Ivermectine is the best prophylactic and therapeutic option, and thiabendazole should no longer be used. However, guidelines for the prevention and management of S. stercoralis infection in such patients have not yet been established.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961629     DOI: 10.1111/j.1469-0691.2006.01443.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Non-oral treatment with ivermectin for disseminated strongyloidiasis.

Authors:  Dahlene N Fusco; Jennifer A Downs; Michael J Satlin; Meera Pahuja; Liz Ramos; Philip S Barie; Lawrence Fleckenstein; Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

Review 2.  Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections.

Authors:  Jaco J Verweij; C Rune Stensvold
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 3.  Strongyloides stercoralis infection in a patient with rheumatoid arthritis and type 2 diabetes mellitus: a case-based review.

Authors:  Alireza Ashiri; Molouk Beiromvand; Abdollah Khanzadeh
Journal:  Clin Rheumatol       Date:  2019-05-23       Impact factor: 2.980

Review 4.  Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries.

Authors:  Ana Requena-Méndez; Dora Buonfrate; Joan Gomez-Junyent; Lorenzo Zammarchi; Zeno Bisoffi; José Muñoz
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

5.  Strongyloidiasis: a case with acute pancreatitis and a literature review.

Authors:  Jasbir Makker; Bhavna Balar; Masooma Niazi; Myrta Daniel
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

6.  Strongyloides hyperinfection syndrome due to corticosteroid therapy after resection of meningioma: illustrative case.

Authors:  Víctor Rodríguez Domínguez; Carlos Pérez-López; Catalina Vivancos Sánchez; Cristina Utrilla Contreras; Alberto Isla Guerrero; María José Abenza Abildúa
Journal:  J Neurosurg Case Lessons       Date:  2022-07-11

Review 7.  Strongyloides stercoralis: Global Distribution and Risk Factors.

Authors:  Fabian Schär; Ulf Trostdorf; Federica Giardina; Virak Khieu; Sinuon Muth; Hanspeter Marti; Penelope Vounatsou; Peter Odermatt
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11

8.  Structural and functional characterization of a novel scFv anti-HSP60 of Strongyloides sp.

Authors:  Marcelo Arantes Levenhagen; Fabiana de Almeida Araújo Santos; Patrícia Tiemi Fujimura; Ana Paula Carneiro; Ana Paula Caneiro; Julia Maria Costa-Cruz; Luiz Ricardo Goulart
Journal:  Sci Rep       Date:  2015-05-21       Impact factor: 4.379

Review 9.  Strongyloidiasis--an insight into its global prevalence and management.

Authors:  Santhosh Puthiyakunnon; Swapna Boddu; Yiji Li; Xiaohong Zhou; Chunmei Wang; Juan Li; Xiaoguang Chen
Journal:  PLoS Negl Trop Dis       Date:  2014-08-14

10.  Disseminated strongyloidiasis complicating glioblastoma therapy: a case report.

Authors:  Dawit Aregawi; David Lopez; Mark Wick; W Michael Scheld; David Schiff
Journal:  J Neurooncol       Date:  2009-03-31       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.